CoChat

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease

Open access
Ferrari-Souza, João Pedro, Ferreira, Pâmela C. L., Bellaver, Bruna, Tissot, Cécile, Wang, Yi-Ting, Leffa, Douglas T., Brum, Wagner S., Benedet, Andréa L., Ashton, Nicholas J., De Bastiani, Marco Antônio, Rocha, Andréia, Therriault, Joseph, Lussier, Firoza Z., Chamoun, Mira, Servaes, Stijn, Bezgin, Gleb, Kang, Min Su, Stevenson, Jenna, Rahmouni, Nesrine, Pallen, Vanessa, Poltronetti, Nina Margherita, Klunk, William E., Tudorascu, Dana L., Cohen, Ann D., Villemagne, Victor L., Gauthier, Serge, Blennow, Kaj, Zetterberg, Henrik, Souza, Diogo O., Karikari, Thomas K., Zimmer, Eduardo R., Rosa-Neto, Pedro, Pascoal, Tharick A. · 2022 · Molecular Psychiatry
Cited by 139

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([ 18 F]AZD4694) and tau ([ 18 F]MK-6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of Aβ and tau, respectively, on hippocampal atrophy, which was further associated with cognitive impairment. Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain Aβ and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01716-2

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 139

Metadata

Authors
Ferrari-Souza, J. P., Ferreira, P. C. L., Bellaver, B., Tissot, C., Wang, Y.-T., Leffa, D. T., Brum, W. S., Benedet, A. L., Ashton, N. J., De Bastiani, M. A., Rocha, A., Therriault, J., Lussier, F. Z., Chamoun, M., Servaes, S., Bezgin, G., Kang, M. S., Stevenson, J., Rahmouni, N., Pallen, V., Poltronetti, N. M., Klunk, W. E., Tudorascu, D. L., Cohen, A. D., Villemagne, V. L., Gauthier, S., Blennow, K., Zetterberg, H., Souza, D. O., Karikari, T. K., Zimmer, E. R., Rosa-Neto, P., & Pascoal, T. A.
Venue
Molecular Psychiatry
Published
2022-08-10
Volume
27
Issue
11
Pages
4781-4789
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4291020647
Cited by
139
References
41
FWCI
14.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41380-022-01716-2
The paper
Ferrari-Souza, J. P., Ferreira, P. C. L., Bellaver, B., Tissot, C., Wang, Y.-T., Leffa, D. T., Brum, W. S., Benedet, A. L., Ashton, N. J., De Bastiani, M. A., Rocha, A., Therriault, J., Lussier, F. Z., Chamoun, M., Servaes, S., Bezgin, G., Kang, M. S., Stevenson, J., Rahmouni, N., . . . Pascoal, T. A. (2022). Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01716-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.